Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

By H. Burris, H. Rugo, S. Vukelja, C. Vogel, R. Borson, S. Limentani, E. Tan-chiu, Ian Krop, R. Michaelson, S. Girish and 5 more. Journal of Clinical Oncology, 2011

724 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/cee8f8b6f9bf597e1a1eabf5d19660cd52025572

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Y. Ogitani
2. K. Hagihara
3. Masataka Oitate
4. T. Agatsuma
5. Takehiro Hirai
6. T. Nakada
7. Hiromi Okamoto
8. J. Yamaguchi

Citations in the corpus

• DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 (2016, background): “Clin Cancer Res; 22(20) October 15, 2016 Clinical Cancer Research5100 www.aacrjournals.org Clin Cancer Res; 22(20) October 15, 2016 5101 2F), and these were comparable or rather lower than those of other ADCs, such as T-DM1, SGN-35 (Brentuximab vedotin), and inotuzumab ozogamicin (35–37).”